Predictive value of serum sTREM1 combined with ABCD-3I score for short-term ischemic stroke in patients with transient ischemic attack

doi:10.11958/20220632

Abstract

Abstract:

Objective To investigate the predictive value of serum soluble triggering receptors expressed on myeloid cells 1 (sTREM1) combined with ABCD-3I score in the prediction of recent acute ischemic stroke (AIS) in patients with transient ischaemic attack (TIA). Methods A total of 288 TIA patients were selected, and they were divided into the low-risk group (102 cases), the intermediate-risk group (131 cases) and the high-risk group (55 cases) according to their ABCD-3I scores. In addition, the patients were sub-divided into the AIS group (41 cases) and the non-AIS group (247 cases) according to whether AIS occurred after 90 days. The clinical data such as age, sex and basic diseases were collected, and the serum sTREM1 level was detected by enzyme-linked immunosorbent assay. Results The age, proportion of diabetes, proportion of hypertension, low-density lipoprotein cholesterol (LDL-C) level, sTREM1 level and AIS ratio were significantly higher in the high-risk group than those in the intermediate-risk group and the low-risk group (P<0.05). The sTREM1 level was significantly higher in the intermediate-risk group than that in the low-risk group (P<0.05). The age, proportion of hypertension, LDL-C level, ABCD-3I score and sTREM1 level were significantly higher in the AIS group than those in the non-AIS group (P<0.05). Multivariate Logistic regression model analysis showed that both higher ABCD-3I score and higher sTREM1 level were risk factors for recent AIS in TIA patients (P<0.05). The area under the curve of ABCD-3I score and sTREM1 level in predicting AIS in TIA patients were 0.795 (95%CI: 0.723-0.867) and 0.755 (95%CI: 0.672-0.839) respectively, and the area under the curve increased to 0.881 (95%CI: 0.830-0.932) after the combination of ABCD-3I score and sTREM1 level. Conclusion Serum sTREM1 combined with ABCD-3I score has a high predictive value for recent AIS in TIA patients, and which has certain clinical application value.

Key words: ischemic attack, transient, stroke, early diagnosis, myelolytic myeloid trigger receptor 1, ABCD-3I score

CLC Number:

R743.31

Figures/Tables 5

References 18

[1]	KLEINDORFER D O, TOWFIGHI A, CHATURVEDI S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack:A guideline from the American Heart Association/American Stroke Association[J]. Stroke,2021, 52(7):e364-e467. doi:10.1161/STR.0000000000000375.
[2]	MENDELSON S J, PRABHAKARAN S. Diagnosis and management of transient ischemic attack and acute ischemic stroke:A review[J]. JAMA, 2021, 325(11):1088-1098. doi:10.1001/jama.2020.26867.
[3]	OLIVEIRA F A A, SAMPAIO ROCHA-FILHO P A. Headaches attributed to ischemic stroke and transient ischemic attack[J]. Headache, 2019, 59(3):469-476. doi:10.1111/head.13478.
[4]	WANG Y, JING J, MENG X, et al. The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack:Design, rationale and baseline patient characteristics[J]. Stroke Vasc Neurol, 2019, 4(3):158-164. doi:10.1136/svn-2019-000242.
[5]	MAYER L, FERRARI J, KREBS S, et al. ABCD3-I score and the risk of early or 3-month stroke recurrence in tissue- and time-based definitions of TIA and minor stroke[J]. J Neurol, 2018, 265(3):530-534. doi:10.1007/s00415-017-8720-8.
[6]	KUNG C T, SU C M, HSIAO S Y, et al. The prognostic value of serum soluble TREM-1 on outcome in adult patients with sepsis[J]. Diagnostics(Basel), 2021, 11(11):1979. doi:10.3390/diagnostics11111979.
[7]	VANDESTIENNE M, JOFFRE J, LEMARIE J, et al. Rôle du récepteur TREM-1 dans les maladies cardiovasculaires [Role of TREM-1 in cardiovascular diseases][J]. Med Sci (Paris), 2022, 38(1):32-37. doi:10.1051/medsci/2021242.
[8]	HUANG J B, CHEN N C, CHEN C L, et al. Serum levels of soluble triggering receptor expressed on myeloid cells-1 associated with the severity and outcome of acute ischemic stroke[J]. J Clin Med, 2020, 10(1):61. doi:10.3390/jcm10010061.
[9]	吴嘉, 时永辉, 程婧, 等. 短暂性脑缺血发作患者血清小而密低密度脂蛋白胆固醇水平升高且与再发卒中风险相关的研究[J]. 中华检验医学杂志, 2018, 41(4):316-320.
	WU J, SHI Y H, CHENG J, et al. The increased level of serum small dense low-density lipoprotein cholesterol in patients with transient ischemic attacks and its correlation with recurrent stroke[J]. Chin J Lab Med, 2018, 41(4):316-320. doi:10.3760/cma.j.issn.1009-9158.2018.04.016.
[10]	AHMADI M, LAUMEIER I, IHL T, et al. A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS):An open-label, randomised controlled trial[J]. Lancet Neurol, 2020, 19(1):49-60. doi:10.1016/S1474-4422(19)30369-2.
[11]	SHAH S, LIANG L, BHANDARY D, et al. Outcomes of medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD² score[J]. Stroke Vasc Neurol, 2021, 6(2):314-318. doi:10.1136/svn-2020-000372.
[12]	SONG B, HU R, PEI L, et al. Dual antiplatelet therapy reduced stroke risk in high-risk patients with transient ischaemic attack assessed by ABCD3-I score[J]. Eur J Neurol, 2019, 26(4):610-616. doi:10.1111/ene.13864.
[13]	JOLLY L, CARRASCO K, SALCEDO-MAGGUILLI M, et al. sTREM-1 is a specific biomarker of TREM-1 pathway activation[J]. Cell Mol Immunol, 2021, 18(8):2054-2056. doi:10.1038/s41423-021-00733-5.
[14]	BACKES F N, DE SOUZA A, BIANCHIN M M. Biomarkers in the prognostic evaluation of ischemic stroke:Is there benefit in the measurements of TREM-1 and TREM-2 in the acute phase?[J]. Clin Biochem, 2021, 98(12):10-16. doi:10.1016/j.clinbiochem.2021.07.016.
[15]	LIANG Y B, SONG P P, ZHU Y H, et al. TREM-1-targeting LP17 attenuates cerebral ischemia-induced neuronal injury by inhibiting oxidative stress and pyroptosis[J]. Biochem Biophys Res Commun, 2020, 529(3):554-561. doi:10.1016/j.bbrc.2020.05.056.
[16]	WANG H M, GAO J H, LU J L. Pravastatin improves atherosclerosis in mice with hyperlipidemia by inhibiting TREM-1/DAP12[J]. Eur Rev Med Pharmacol Sci, 2018, 22(15):4995-5003. doi:10.26355/eurrev_201808_15640.
[17]	XU P, ZHANG X, LIU Q, et al. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke[J]. Cell Death Dis, 2019, 10(8):555. doi:10.1038/s41419-019-1777-9.
[18]	SOLANKI A, BHATT L K, JOHNSTON T P. Evolving targets for the treatment of atherosclerosis[J]. Pharmacol Ther, 2018, 187(7):1-12. doi:10.1016/j.pharmthera.2018.02.002.

组别	TG （mmol/L）				ALT （U/L）			Scr （μmol/L）			sTREM1 （ng/L）				AIS
低危组	1.67±0.53				14.78±5.98			77.89±20.56			21.31±5.98				8（7.84）
中危组	1.72±0.57				15.89±6.21			83.57±22.35			26.29±7.33^a				18（13.74）
高危组	1.75±0.51				15.43±6.15			80.69±21.32			31.68±8.45^ab				15（27.27）^ab
F或χ²	0.443				0.927			2.010			39.403^＊＊				11.097^＊＊
组别		高血压				高脂血症			吸烟史			TC （mmol/L）		LDL-C （mmol/L）
低危组		33（32.35）				20（19.61）			42（41.18）			4.98±0.78		3.94±0.77
中危组		52（39.69）				37（28.24）			65（49.62）			5.06±0.94		4.02±0.79
高危组		36（65.45）^ab				20（36.36）			30（54.55）			5.12±0.87		4.33±0.84^ab
F或χ²		16.602^＊＊				5.401			2.965			0.504		4.506^＊
组别			n	年龄（岁）			性别（男/女）			BMI（kg/m²）			糖尿病
低危组			102	55.64±6.35			58/44			22.18±1.42			21（20.59）
中危组			131	57.31±9.62			73/58			22.09±1.53			42（32.06）
高危组			55	61.43±5.93^ab			31/24			22.21±1.61			26（47.27）^ab
F或χ²				9.577^＊＊			0.031			0.157			12.067^＊＊

组别	TG （mmol/L）				ALT （U/L）			Scr （μmol/L）			sTREM1 （ng/L）				AIS
低危组	1.67±0.53				14.78±5.98			77.89±20.56			21.31±5.98				8（7.84）
中危组	1.72±0.57				15.89±6.21			83.57±22.35			26.29±7.33^a				18（13.74）
高危组	1.75±0.51				15.43±6.15			80.69±21.32			31.68±8.45^ab				15（27.27）^ab
F或χ²	0.443				0.927			2.010			39.403^＊＊				11.097^＊＊
组别		高血压				高脂血症			吸烟史			TC （mmol/L）		LDL-C （mmol/L）
低危组		33（32.35）				20（19.61）			42（41.18）			4.98±0.78		3.94±0.77
中危组		52（39.69）				37（28.24）			65（49.62）			5.06±0.94		4.02±0.79
高危组		36（65.45）^ab				20（36.36）			30（54.55）			5.12±0.87		4.33±0.84^ab
F或χ²		16.602^＊＊				5.401			2.965			0.504		4.506^＊
组别			n	年龄（岁）			性别（男/女）			BMI（kg/m²）			糖尿病
低危组			102	55.64±6.35			58/44			22.18±1.42			21（20.59）
中危组			131	57.31±9.62			73/58			22.09±1.53			42（32.06）
高危组			55	61.43±5.93^ab			31/24			22.21±1.61			26（47.27）^ab
F或χ²				9.577^＊＊			0.031			0.157			12.067^＊＊

组别			n	年龄（岁）			性别（男/女）			BMI（kg/m²）			糖尿病
非AIS组			247	57.03±9.54			138/109			22.16±1.56			71（28.74）
AIS组			41	60.34±6.12			24/17			22.32±1.40			18（43.90）
t或χ²				2.148^＊			0.102			0.617			3.783
组别		高血压			高脂血症			吸烟史			TC （mmol/L）				LDL-C （mmol/L）
非AIS组		97（39.27）			63（25.51）			115（46.56）			5.03±0.95				3.99±0.79
AIS组		24（58.54）			14（34.15）			22（53.66）			5.13±0.72				4.39±0.74
t或χ²		5.357^＊			1.340			0.711			0.644				3.029^＊
组别	TG （mmol/L）					ALT （U/L）			Scr （μmol/L）			ABCD-3I 评分（分）		sTREM1 （ng/L）
非AIS组	1.70±0.58					15.47±6.58			80.41±23.52			4.83±1.26		23.92±7.65
AIS组	1.77±0.55					15.06±5.92			84.59±21.73			6.87±1.32		35.42±8.13
t或χ²	0.721					0.375			1.065			9.536^＊＊		8.835^＊＊

组别			n	年龄（岁）			性别（男/女）			BMI（kg/m²）			糖尿病
非AIS组			247	57.03±9.54			138/109			22.16±1.56			71（28.74）
AIS组			41	60.34±6.12			24/17			22.32±1.40			18（43.90）
t或χ²				2.148^＊			0.102			0.617			3.783
组别		高血压			高脂血症			吸烟史			TC （mmol/L）				LDL-C （mmol/L）
非AIS组		97（39.27）			63（25.51）			115（46.56）			5.03±0.95				3.99±0.79
AIS组		24（58.54）			14（34.15）			22（53.66）			5.13±0.72				4.39±0.74
t或χ²		5.357^＊			1.340			0.711			0.644				3.029^＊
组别	TG （mmol/L）					ALT （U/L）			Scr （μmol/L）			ABCD-3I 评分（分）		sTREM1 （ng/L）
非AIS组	1.70±0.58					15.47±6.58			80.41±23.52			4.83±1.26		23.92±7.65
AIS组	1.77±0.55					15.06±5.92			84.59±21.73			6.87±1.32		35.42±8.13
t或χ²	0.721					0.375			1.065			9.536^＊＊		8.835^＊＊

指标	β	SE	Wald χ²	P	OR	OR 95%CI
LDL-C	0.233	0.193	1.457	0.227	1.262	0.865~1.843
ABCD-3I评分	0.707	0.263	7.226	0.007	2.028	1.211~3.396
sTREM1	0.541	0.178	9.238	0.002	1.718	1.212~2.435
常数项	0.311	0.124	6.290	0.012	1.365	-